Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases

Abstract

IntroductionTo further assess the efficacy of QVA149 compared with SFC in LANTERN and ILLUMINATE studies, we performed a pooled analysis of the overall data and also in the GOLD B and D patient (pt) subgroups.MethodsData was pooled from two 26-week (wk) double-blind studies in symptomatic COPD pts randomised to QVA149 110/50mg od or SFC 50/500mg bid. Endpoints were FEV₁ AUC_0–12h, peak FEV₁, peak FVC, pre-dose trough FEV₁, pre-dose trough FVC, TDI, SGRQ, rescue medication use and safety.ResultsIn total, 1263 pts were divided into GOLD B (n=809) and GOLD D (n=454) subgroups (GOLD 2014). QVA149 demonstrated statistically significant improvement in lung function vs. SFC (Table) at Wk 26. Changes from baseline in TDI and rescue medication use were statistically significant with QVA149 vs. SFC in overall population and in GOLD B (TDI only) and in GOLD D (rescue medication only) subgroups (Table). QVA149 also reduced exacerbations in the pooled analysis. Adverse events were similar between QVA149 (295) and SFC (335), with a lower incidence of pneumonia with QVA149 (14 vs 3).



ConclusionIn this pooled analysis, QVA149 demonstrated better efficacy than SFC in overall population and in GOLD B and GOLD D patients in all lung function parameters tested. This supports the use of QVA149 over SFC in symptomatic patients with COPD.


Rating:

Share or cite this content

Citations should be made in the following way:
Claus Vogelmeier (Marburg, Germany), Claus Vogelmeier, Nanshan Zhong, Karen Mezzi, Robert Fogel, Donald Banerji. Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis. Eur Respir J 2015; 46: Suppl. 59, 2965

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Once-daily indacaterol 150µg or 300µg and other bronchodilators in COPD patients of GOLD 2011 groups A and B Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016